Dark Forest Capital Management LP acquires 35,562 shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

Dark Forest Capital Management LP boosted its holdings in Verve Therapeutics, Inc. (NASDAQ:VERV – Free Report) by 301.4% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 47,361 shares of the company’s stock after purchasing an additional 35,562 shares during the period. Dark Forest Capital Management LP owned about 0.06% of Verve Therapeutics worth $231,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of VERV. Vanguard Group Inc. raised its position in Verve Therapeutics by 15.7% in the first quarter. Vanguard Group Inc. now owns 6,331,312 shares of the company’s stock worth $84,080,000 after acquiring an additional 859,382 shares during the period. Cubist Systematic Strategies LLC boosted its holdings in shares of Verve Therapeutics by 245.5% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 395,699 shares of the company’s stock valued at $1,931,000 after acquiring an additional 281,173 shares during the period. during the period. Renaissance Technologies LLC boosted its stake in Verve Therapeutics by 138.1% in the second quarter. Renaissance Technologies LLC now owns 474,500 shares of the company’s stock valued at $2,316,000 after buying an additional 275,173 shares during the period. Los Angeles Capital Management LLC purchased a new stake in Verve Therapeutics in the second quarter valued at about $1,183,000. Finally, Nikko Asset Management Americas Inc. raised its stake in Verve Therapeutics by 8.1% in the first quarter. Nikko Asset Management Americas Inc. now owns 2,592,198 shares of the company’s stock valued at $34,347,000 after acquiring an additional 194,594 shares during the period. 97.11% of shares are currently owned by institutional investors and hedge funds.

Analysts on Wall Street are forecasting an increase

A number of analysts have recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Verve Therapeutics in a research report on Monday, August 12th. Royal Bank of Canada lowered their price objective on shares of Verve Therapeutics from $25.00 to $20.00 and set an “outperform” rating for the company in a report on Friday, August 9th. Finally, Canaccord Genuity Group dropped their target price on shares of Verve Therapeutics from $30.00 to $29.00 and set a “buy” rating on the stock in a research note on Monday, 12 August. Five investment analysts have rated the stock with a buy rating. The stock presently has a consensus rating of “Buy” and an average price target of $26.00, according to MarketBeat.com.

See our latest report on VERV

Verve Therapeutics Stock Performance

Shares of NASDAQ:VERV opened at $4.98 on Monday. The company’s fifty day moving average is $5.72 and its 200 day moving average is $6.65. Verve Therapeutics, Inc. has a 52-week low of $4.30 and a 52-week high of $20.12. The company has a market cap of $418.15 million, a PE ratio of -1.74 and a beta of 1.83.

Verve Therapeutics (NASDAQ:VERV – Get Your Free Report ) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.09. Verve Therapeutics had a negative net margin of 933.08% and a negative return on equity of 35.20%. The company had revenue of $6.70 million for the quarter, compared to analysts’ expectations of $2.40 million. During the same period in the previous year, the firm earned ($0.87) earnings per share. The company’s quarterly revenue was up 219.0% compared to the same quarter last year. On average, analysts estimate that Verve Therapeutics, Inc. will post -2.65 EPS for the current year.

Verve Therapeutics Profile

(Free Report)

Verve Therapeutics, Inc, a clinical stage gene medicine company, is engaged in the development of gene editing medicines for patients to treat cardiovascular disease in the United States. The company’s lead product candidate is VERVE-101, a single-course gene-editing treatment that permanently shuts down the PCSK9 gene in the liver; and VERVE-102, a product candidate targeting the PCSK9 gene for the treatment of HeFH.

Read more

Get news and reviews for Verve Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Verve Therapeutics and related companies with MarketBeat.com ‘s FREE daily email newsletter.